Member Info for optrade

UK banks are in better shape than EU banks. UK Insurance & property shares oversold, lower pound good for London. L&G with solid results should be over 200P rising to 250P+ before year end in my opinion.

In sales for its Retirement division in the half year to the end of June, covering bulk annuities, individual annuities and lifetime mortgages.

Bounce coming soon in my opinion

I disagree, 200m has already been allocated @15P market cap only £1.5m as explained in my last post here which should be around the low, lucky for some they can buy less than that now, great time to get in, contract news RNS any time soon. Good luck if you are shorting at year lows with improved trading

200m shares, the majority have already been placed to raise £250,000 1,039.76m existing will become 1,239m shares in issue on June 6th 166,666,800 new ordinary shares of 0.1p each (“Ordinary Shares”) with existing and new institutional investors (the “Placing Shares”) arranged by Hybridan LLP and that, in addition, it will issue 33,333,333 new Ordinary Shares to City and Claremont Capital Assets Ltd following the conversion of loan interest amounting to £50,000 (the “Conversion Shares”), in each case at a price of 0.15p per Ordinary Share (the “Issue Price”). Transformative projects................ Quote from trading performance RNS end of April 2016: The Group has already closed almost £1 million of new business to be delivered in 2016 and is currently pitching on several large projects. Two of these projects, in particular, have the potential to be transformative for the business.

25-May-1608:18:56414.9333300,000Buy* 411.60412.50 1.245M Looks like Paysafe is heading for new highs, been rising since 2015

Despite a small full year loss...PTCM is unlikely to skyrocket, steady progress has been made and it has some good group assets all doing well. SP should rise over medium to long term, target 10P + if the results continue to improve. Fairly safe investment imo. BUY / HOLD.

Wife of to be exact, there is a very close spread right now whatever that means. It's trying to rally except someone is also selling a lot, we will have to see who wins. If the RNS is anything to go by we should be moving up.

Could hardly be better, SP heading back into 40's

Best ever financial performance for year ending 31st March 2016 but still a small overall annual loss however it appears they have a loyal growing blue chip growing customer base and should be soon cash flow positive. There should be new contract news soon, two of which will be very lucrative if signed, also news of a new Financial Director. With market cap of only 2 million this stock looks very undervalued and it does not take much to move the SP. Good time to top-up imo.

QUOTE: "Extremely satisfying performance for this first quarter of 2016. It is an excellent start to the year and puts Serabi in a strong position to meet our guidance of 37,000 ounces." This could quickly re-rate to 6-7.5p in my opinion, still some way to go.

Congratz if they have been correct, and they still might be... all PI's are interested are facts or future and to knock every positive RNS does seem odd even if I can understand it. We will have to wait and see to see if there is a turning point, if it comes it could be big.

"Today's RNS should have been the start of something new" It still could be imo. It is down, de-rampers are not always so that they can buy in cheap and I didn't name anyone. I'm not looking to stop them to post as they will always be here as will holders, always looking for a balanced viewpoint. Yes I hold FLX and will not sell unless we see facts that show he bods strategy is not working which there are none. There is risk but the SP is already looking cheap imo.

Yes say what you think but if you are not currently invested it's best to move on otherwise it looks like you have a chip to bear, in my opinion things could turn around very fast, besides we shouldn't knock it when they release a RNS despite not knowing what it will be worth There is quite a lot happening with FLX taking over ASC, new Health foundation contract and the chairman investing £50,000 so it's could be all pie in the sky as you say or it just may not be. Keep posting and I will pay attention.

Looks like they are putting their money where their mouth is, @ 4P with options for more @ 6P. To the de-rampers here, if you don't like what FLX is doing please move on.

There is good news in the RNS nothing to warrant another 5% drop. The company has re-positioned itself to benefit from a potentially very lucrative security market with strong government connections that take time to produce. Firm hold / add in my opinion

Nevertheless the growth is better than some expected, the company has a sound business model and is able to adapt and still show good profit in a market of fluctuating energy prices. Investors are generally pleased with yesterdays trading update with a maintained dividend, yes it could be better but you can say that about most companies. The results are still the best they have achieved, rocket growth is for younger less established companies with much higher risk imo. If you look at past SP above 1000P the shares look cheap with only 80m in circulation a re-rate could easily happen.

If you agree or not the market like the results,. the SP is up more than 5% today! If you haven't looked there is not a broker with an SP target below 1000P

Solid trading update, TEP is on it's way back up.

LONDON (Alliance News) - Quantum Pharma PLC on Tuesday said its Colonis Pharma Ltd unit has received UK marketing approval for two new strengths of Vitamin D capsules from the Medicines & Healthcare products Regulatory Agency. The 800 IU and 1,000 IU capsules are in both branded and generic versions, Quantum said, giving a total of four new licensed products. Quote: LONDON (Alliance News) - Quantum Pharma PLC on Tuesday said its Colonis Pharma Ltd unit has received UK marketing approval for two new strengths of Vitamin D capsules from the Medicines & Healthcare products Regulatory Agency. The 800 IU and 1,000 IU capsules are in both branded and generic versions, Quantum said, giving a total of four new licensed products. "We are delighted to receive licences for these two new strengths of our Vitamin D range in both branded and generic presentations. Vitamin D deficiency is a growing market in which we are seeking to become a significant player through our commitment to developing a broad product range," said Andrew Scaife, Quantum's chief executive.